Home > Insider Trading > Filing (0000950170-25-082498)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
818686	Teva Pharmaceutical Industries Ltd	TEVA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
2025621	Matthew Shields	C/O Teva Pharmaceutical Industries Ltd. 124 Dvora Hanevi'A St., Tel Aviv L3 6944020	Evp, Global Operations	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Acquisiton	2025-06-03	16,195	$0.00	16,195	No	4	M	Direct
Ordinary Shares	Disposition	2025-06-03	6,206	$17.02	9,989	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Restricted Share Units	Disposition	2025-06-03	16,195	$0.00	16,195	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
48,587			No	4	M	Direct

Footnotes

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
Restricted share units were granted on June 3, 2024 with 16,195 vested on June 3, 2025, 16,195 vesting on each of June 3, 2026 and June 3, 2027, and 16,197 vesting on June 3, 2028.